Tech Company Financing Transactions
Jazz Pharmaceuticals Funding Round
Jazz Pharmaceuticals closed a $250 million Series B funding round on 3/24/2004. Investors included Adams Harkness Ventures, EGS Healthcare Capital Partners and Golden Gate Capital.
Transaction Overview
Company Name
Announced On
3/24/2004
Transaction Type
Venture Equity
Amount
$250,000,000
Round
Series B
Investors
Proceeds Purpose
This financing enables us to simultaneously build our commercial organization and expand our portfolio of early and late-stage development projects, thereby creating robust neurology and psychiatry franchises
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
Waterloo Rd. Waterloo Exchange
Dublin 4, CA D04
Ireland
Dublin 4, CA D04
Ireland
Phone
Website
Email Address
Overview
Jazz (Nasdaq: JAZZ) is a pharmaceutical company focusing on improving the lives of patients through the development and commercialization of neurological and psychiatric products. We are committed to working closely with patients, patient advocacy groups and healthcare professionals.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Bruce Cozadd
Chief Financial Officer
Renée Galá
Chief Operating Officer
Daniel Swisher
Executive Vice President
Michael Miller
VP - Engineering
Finbar Larkin
VP - Human Resources
Heidi Manna
VP - R & D
Robert Iannone
Browse more venture capital transactions:
Prev: 3/24/2004: VideoCodes venture capital transaction
Next: 3/24/2004: CloudShield Technologies venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs